medigraphic.com

2012, Number 3

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2012; 50 (3)

The evaluation and treatment of a patient with atrial fibrillation

Moreno-Ruiz LA, Rodríguez-Piña H, Martínez-Flores JE

Language: Spanish
References: 28
Page: 273-284
PDF size: 217.52 Kb.


ABSTRACT

Atrial fibrillation (AF) is the most common arrhythmia in humans. The treatment can be one of the most difficult. It’s true that AF itself it’s a no-lethal arrhythmia but is often a cause of symptoms that can lead the patient to worsening in his quality of life thet predispose to serious conditions like thromboembolic events and heart failure. There is a general agreement in the benefit of antithrombotic therapy and the need of control of comorbid conditions, but there is not an ideal treatment for AF and the choice for the best treatment is based on the individual differences of each patient. Physician and patient must be aware of the risks and possible complications as well as the options in antiarrhythmic and antithrombotic drugs available in order to choose the best for each patient. We must get the message across that AF patients show a dynamic curse of the disease so reevaluation of the individual risk and response to therapy should be made.


REFERENCES

  1. Guía de práctica clínica, diagnóstico y tratamiento de la fibrilación auricular. México: Secretaría de Salud. Actualizada en febrero de 2011. Disponible en http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/014_GPC_FibrilacionAuricular/SS_014_08_EyR.pdf

  2. Fuster V, Ryde´n LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123(10):e269-e367. Disponible en http://circ.ahajournals.org/content/123/10/e269.long

  3. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guías de práctica clínica para el manejo de la fibrilación auricular. Rev Esp Cardiol 2010;63(12):1483.e1-e83.

  4. Khoo CW, Krishnamoorthy S, Lim HS, Lip GYH. Atrial fibrillation, arrhythmia burden and thrombogenesis. Int J Cardiol 2011;318-323.

  5. Iturralde-Torres P, Lara-Vaca S, Cordero-Cabra A, Nava- Townsend S, Mendoza C, Márquez MF, et al. Diseño de un registro multicéntrico para evaluar control de ritmo contra control de la frecuencia en fibrilación auricular: Registro Mexicano de Fibrilación Auricular (ReMeFA). Arch Cardiol Mex 2011;81(1):13-17.

  6. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation-a translational appraisal. Physiol Rev 2011;91(1):265-325.

  7. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339(10):659-666. Disponible en http://dx.doi.org/10.1056/NEJM199809033391003

  8. Jalife J. Déjà vu in the theories of atrial fibrillation dynamics. Cardiovasc Res 2011;89(4):766-775. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105592/?tool=pubmed

  9. Ziegler PD, Koehler JL, Mehra R. Comparison of continuous versus intermittent monitoring of atrial arrhythmias. Heart Rhythm 2006;3(12):1445-1452.

  10. Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D, et al. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: results of the XPECT trial. Circ Arrhythm Electrophysiol 2010;3(2):141-147. Disponible en http://circep.ahajournals.org/content/3/2/141.long

  11. Hohnloser SH, Connolly SJ, Crijns HJ, Page RL, Seiz W, Torp-Petersen C. Rationale and design of ATHENA: a placebo-controlled, double-blind, parallel arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol 2008;19(1):69-73.

  12. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342: d124. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3031123/?tool=pubmed

  13. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170(16):1433-1441.

  14. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360(20):2066-2078. Disponible en http://dx.doi.org/10.1056/NEJMoa0901301

  15. Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 123(10):1144-1450. Disponible en http://content.onlinejacc.org/cgi/pmidlookup?view=long&pmid= 21324629

  16. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarinassociated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011;58(4):395-401.

  17. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151(3):713-719.

  18. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123(1):104-123. Disponible en http://circ.ahajournals.org/content/123/1/104.long

  19. Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JG, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004;43(2):241-247.

  20. Doyle JF, Ho KM. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis. Mayo Clin Proc 2009;84(3):234-242. Disponible en http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2664595/?tool=pubmed

  21. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352(18):1861-1872.

  22. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365(24):2268-2276. Disponible en http://dx.doi.org/10.1056/NEJMoa1109867

  23. Boersma LV, Castella M, van Boven W, Berruezo A, Yilmaz A, Nadal M, et al. Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial. Circulation 2012;125(1):23-30.

  24. Roux JF, Zado E, Callans DJ, Garcia F, Lin D, Marchlinski FE, et al. Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study). Circulation 2009;120(12):1036-1040. Disponible en http://circ.ahajournals.org/content/120/12/1036.long

  25. Hoyt H, Bhonsale A, Chilukuri K, Alhumaid F, Needleman M, Edwards D, et al. Complications arising from catheter ablation of atrial fibrillation: temporal trends and predictors. Heart Rhythm 2011;8(12):1869-1874.

  26. Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011;364(10):928-938. Disponible en http://dx.doi.org/10.1056/NEJMoa1008816

  27. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensin- converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45(11):1832-1839.

  28. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008;51(8):828-835. Disponible en http://content.onlinejacc.org/cgi/pmidlookup?view=long&pmid=18294568




2020     |     www.medigraphic.com